Fennec Pharmaceuticals (FENC) Payables (2010 - 2026)
Fennec Pharmaceuticals' (FENC) quarterly Payables came in at $4.6 million in Q4 2025, up 43.01% YoY from $3.2 million in Q4 2024, and down 20.99% on a QoQ basis from $5.9 million in Q3 2025.
Analysis
Fennec Pharmaceuticals (FENC) Payables (2010 - 2026) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 16 years of Payables data on file, last reported at $4.6 million in Q4 2025.
- Quarterly Payables rose 43.01% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.6 million (up 43.01% YoY) and the FY2025 annual result came in at $4.6 million, up 43.01% from the prior year.
- Payables slipped to $4.6 million in Q4 2025, from $5.9 million in the prior quarter.
- In the past five years, Payables ranged from a high of $5.9 million in Q2 2025 to a low of $677000.0 in Q2 2021.
- A 5-year average of $3.2 million and a median of $3.0 million in 2023 frame the typical range for Payables.
- Annual changes were most pronounced in 2021 — Payables plunged 75.43% — and 2022, when it surged 207.59%.
- Tracing FENC's Payables over 5 years: stood at $777000.0 in 2021, then surged by 207.59% to $2.4 million in 2022, then surged by 58.08% to $3.8 million in 2023, then declined by 14.21% to $3.2 million in 2024, then jumped by 43.01% to $4.6 million in 2025.
- The last three Payables figures came in at $4.6 million (Q4 2025), $5.9 million (Q3 2025), and $5.9 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Fennec Pharmaceuticals | 432.85 Mn | 391.60 Mn | 17.15 Mn | 5.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.52 Mn |
| Dec 31, 2025 | 4.64 Mn |
| Sep 30, 2025 | 5.87 Mn |
| Jun 30, 2025 | 5.94 Mn |
| Mar 31, 2025 | 5.28 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 3.87 Mn |
| Jun 30, 2024 | 4.45 Mn |
| Mar 31, 2024 | 5.20 Mn |
| Dec 31, 2023 | 3.78 Mn |
| Sep 30, 2023 | 2.94 Mn |
| Jun 30, 2023 | 3.01 Mn |
| Mar 31, 2023 | 2.95 Mn |
| Dec 31, 2022 | 2.39 Mn |
| Sep 30, 2022 | 2.53 Mn |
| Jun 30, 2022 | 1.74 Mn |
| Mar 31, 2022 | 1.22 Mn |
| Dec 31, 2021 | 777,000.00 |
| Sep 30, 2021 | 1.15 Mn |
| Jun 30, 2021 | 677,000.00 |